PharVision Advisers’s EPAM Systems EPAM Stock Holding History

PharVision Advisers’s Portfolio EPAM Stock Details EPAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,397	Closed	-$211K	–	776
2025 Q3	$211K	Sell	1,397 -450	-24%	-$73.9K	0.12%	472
2025 Q2	$327K	Buy	+1,847	New	+$309K	0.47%	64
2025 Q1	–	Sell	-1,464	Closed	-$342K	–	343
2024 Q4	$342K	Buy	+1,464	New	+$326K	0.29%	115

Other funds holding EPAM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PharVision Advisers's EPAM Position: Q4 2025 in Review

PharVision Advisers sold out of EPAM Systems (EPAM) in Q4 2025, closing a stake of 1,397 shares — an estimated $211K sold.

PharVision Advisers first reported a position in EPAM in Q4 2024 and held it in 3 quarters. The position peaked at $342K in Q4 2024. 596 funds tracked by Wall St. Rank hold EPAM as of Q4 2025.

PharVision Advisers reported no remaining EPAM Systems position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 1,397 EPAM Systems shares in Q4 2025, an estimated $211K.
PharVision Advisers first reported a position in EPAM Systems in Q4 2024 and held it in 3 quarters.
PharVision Advisers's EPAM Systems position peaked at $342K in Q4 2024.
596 funds tracked by Wall St. Rank held EPAM Systems as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.